HomeCompareMVES vs MRK

MVES vs MRK: Dividend Comparison 2026

MVES yields 97560.98% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MVES wins by $3.776305572355012e+26M in total portfolio value
10 years
MVES
MVES
● Live price
97560.98%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.776305572355012e+26M
Annual income
$376,870,661,561,253,050,000,000,000,000,000.00
Full MVES calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — MVES vs MRK

📍 MVES pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMVESMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MVES + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MVES pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MVES
Annual income on $10K today (after 15% tax)
$8,292,682.93/yr
After 10yr DRIP, annual income (after tax)
$320,340,062,327,065,100,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MVES beats the other by $320,340,062,327,065,100,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MVES + MRK for your $10,000?

MVES: 50%MRK: 50%
100% MRK50/50100% MVES
Portfolio after 10yr
$1.888152786177506e+26M
Annual income
$188,435,330,780,626,520,000,000,000,000,000.00/yr
Blended yield
99.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MVES
No analyst data
Altman Z
-1478.2
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MVES buys
0
MRK buys
0
No recent congressional trades found for MVES or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMVESMRK
Forward yield97560.98%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$3.776305572355012e+26M$56.8K
Annual income after 10y$376,870,661,561,253,050,000,000,000,000,000.00$9,798.13
Total dividends collected$3.775807569040114e+26M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MVES vs MRK ($10,000, DRIP)

YearMVES PortfolioMVES Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$9,766,798$9,756,097.56$11,206$366.19+$9.76MMVES
2$8,915,668,218$8,905,217,744.22$12,650$502.35+$8915.66MMVES
3$7,606,895,774,454$7,597,356,009,460.71$14,407$694.19+$7606895.76MMVES
4$6,066,181,203,275,186$6,058,041,824,796,520.00$16,585$967.82+$6066181203.26MMVES
5$4,521,476,760,610,756,600$4,514,985,946,723,252,000.00$19,342$1,363.89+$4521476760610.74MMVES
6$3,149,960,361,765,127,000,000$3,145,122,381,631,274,000,000.00$22,913$1,947.19+$3149960361765127.00MMVES
7$2,051,128,108,701,665,300,000,000$2,047,757,651,114,576,600,000,000.00$27,662$2,823.89+$2051128108701665280.00MMVES
8$1,248,379,585,384,790,000,000,000,000$1,246,184,878,308,479,300,000,000,000.00$34,159$4,173.35+$1.24837958538479e+21MMVES
9$710,182,873,129,118,200,000,000,000,000$708,847,106,972,756,500,000,000,000,000.00$43,337$6,308.80+$7.101828731291182e+23MMVES
10$377,630,557,235,501,200,000,000,000,000,000$376,870,661,561,253,050,000,000,000,000,000.00$56,776$9,798.13+$3.776305572355012e+26MMVES

MVES vs MRK: Complete Analysis 2026

MVESStock

The Movie Studio, Inc. operates as a vertically integrated motion picture production and distribution company. It focuses on acquiring, developing, producing, and distributing independent motion picture content for consumption via subscription and advertiser video on demand (SVOD/AVOD), over the top (OTT) platforms, foreign sales, and various media devices. The company is establishing its own OTT VOD platform to integrate its own and aggregated feature film projects, television programming, and other media intellectual properties. It is disrupting traditional media content delivery systems with its digital business model of motion picture distribution, and intends to create a direct server access platform of its content with geo-fractured territories for worldwide distribution. The company was formerly known as Destination Television, Inc. and changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio, Inc. was incorporated in 1961 and is headquartered in Fort Lauderdale, Florida.

Full MVES Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MVES vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MVES vs SCHDMVES vs JEPIMVES vs OMVES vs KOMVES vs MAINMVES vs JNJMVES vs ABBVMVES vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.